• Envoy Medical posted a net loss of USD 4.35 million, narrowing 12.9% from a year earlier.
• Operating loss widened 16.7% to USD 5.96 million as research and development expense climbed 32.5% to USD 3.64 million.
• Net revenues slipped 15.2% to USD 39,000 while cost of goods sold rose 38.5% to USD 313,000.
• Cash rose to USD 25.25 million at March 31, 2026, from USD 3.74 million at Dec. 31, 2025, with financing cash inflows of USD 27.57 million.
• Acclaim CI pivotal study had all 56 patients enrolled, with first patients reaching 12-month follow-up; FDA decision on planned PMA filing targeted for second half of 2027, extending to first half of 2028 if a panel review is requested.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054209), on May 11, 2026, and is solely responsible for the information contained therein.